End stage liver disease is the final stage of acute or chronic liver damage and is irreversibly associated with liver failure. End stage liver disease can develop rapidly, over days or weeks (acute and sub-acute liver failure, respectively), or gradually, over months or years (chronic liver failure). Currently, liver transplantation is the most effective therapy for patients with end stage liver disease. However, its potential benefits are hampered by many drawbacks, such as the relative shortage of donors, operative risk, post-transplant rejection, recidivism of the pre-existing liver disease, and high costs. The main goals of the health care system for patients with chronic diseases are to prevent additional ill health and to facilitate a life without compromised activities of daily living. The Short Form-36 (SF-36) health survey is a generic health status measurement consisting of 36 items in eight domains, which has demonstrated good reliability and validity in chronic disease populations, including patients with chronic liver diseases.Aim of the work: To assess the effect of stem cell therapy on the health-related quality of life (HRQoL) in patient with end stage liver disease using Short Form-36. Conclusion: Stem cell transplantation has a beneficial effect on synthetic function of the liver and possibly improves survival and quality of life of patients with end stage liver disease. Hepatocyte transplantation may not be able to reverse portal hypertension, or the development of HCC, but improvement in the patient’s quality of life and liver physiology and patient survival could be possible and could play a significant role in the management of patients with liver failure.